28 Nov 2006 - Arrow Therapeutics, a London based antiviral drug discovery and development company, has announced that it has initiated a Phase I study of A-831, a small molecule antiviral inhibitor of Hepatitis C infection. The study shall evaluate the safety, tolerability and pharmacokinetics of single escalating doses of A-831 in healthy volunteers in the UK.
A-831 targets the NS5a protein and is, according to the company, the first NS5a inhibitor to enter the clinic. A-831 is the first compound from Arrow's approach to the NS5a target. A further Arrow compound, also targeting the NS5a protein but of a completely different chemical structure, is expected to enter preclinical development shortly.
 |
www.bionity.com/news/e/59728 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/59728 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |